Secarna strives to become the partner of choice for antisense oligonucleotides (ASO) drug discovery and development programs.

Our flexible partnership model is set to accommodate the best mix of in-house and partner collaborations. Three typical structures are found in our partnership portfolio:

Program Licenses: Single asset deals to out-license high-value, assets for further development and commercialization by partners

Discovery & Research Alliances: Platform deals for multiple-asset discovery and development collaborations leveraging Secarna’s entire toolbox to generate partnered and co-owned ASO pipelines

In-house development: High value programs progressed to and through early-stage clinical studies followed by the potential out-licensing of these candidates to partners